Brit scientist on verge of curing MS

#1
http://www.mirror.co.uk/science/brit-sci...e-10572223

"More than 2.3million people globally are affected by the debilitating condition and symptoms include blindness and muscle weakness.

Dr Metcalfe told the Cambridge News : “Some people get progressive MS, so go straight to the severe form of the disease, but the majority have a relapsing or remitting version,” she says.

“It can start from the age of 30, and there’s no cure, so all you can do is suppress the immune response, but the drugs that do that have side effects, and you can’t repair the brain. The cost of those drugs is very high, and in the UK there are a lot of people who don’t get treated at all.”
Reply
#2
The Article reads like an Advatorial.
there is no link between immune system & re-generation of brain cells & spinal cells(nerve tissue)
there is just a "hop" with no explanation.
the quotes are all open with none closed.
there is no firm line between what the Scientist has said & the writer is saying.

from my basic first Glance it appears the Article is written for people with no attention span to garner some type of "belief"(instead of science) probably in an attempt to get money.

summarily it almost covertly elludes to nano technology as its primary reliant system of action which is quite clearly a fair way off assuming the solving of a workbale safe soluble carrier life span can be extended.

i hope for the scientist sake an actual science reporter writes a proper article on the development.

Who & What is LIFnano ?

Quote:LIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF)..

http://www.lifnano.com/about.shtml
Su Metcalfe PhD (Founder, Chief Scientific Officer, Director)

[Image: 100-metcalfe-bw.jpg]



Quote:LIFNano Therapeutics is now taking LIF to patients.

Quote:For investors
LIFNanoRx holds a robust intellectual property position
LIFNano Therapeutics Intellectual Property portfolio comprises five patent families covering formulations and methods of use for LIF nanoparticles. The Company's filing strategy has preserved substantial scope for further broadening of method claims to encompass other therapeutic uses and extend patent life.
Our Freedom to Operate includes world-wide exclusive license to the two LIFNano patents: one covering immune-linked indications; the second neurodegenerative diseases.
Should you be interested in discussing potential investment opportunities, we would of course be delighted to hear from you. Please [email=invest%40l%69%66n%61no.%63o%6D]contact us by email[/email] in the first instance.


[Image: 600-BinSwitch-noborder.jpg]


Quote:When a T lymphocyte is activated by its antigen, it matures into either a tolerant T cell "Treg" or an effector cell, eg the inflammatory "Th17" cell. This is a critical fate-decision fork permitting self-tolerance to co-exist with immune attack against pathogens. If it goes wrong, auto-immune disease could result should naturally self-tolerant T cells become improperly switched towards self-attack - as occurs in MS where rogue TH17 cells start to attack myelin. A simple binary switch between LIF (for tolerance) and IL-6 (for inflammation) plays a critical role in regulating this fate decision fork - each exerting mutually opposing effects on the other. In auto-immune disease, LIFNano guides the switch for tolerance so protecting against autoimmunity.

it pains me to see cutting edge science rendered to pop art vouyerism by inadequate journalism.
thus i have posted a few items above so people can quickly gather real information.
Reply




Users browsing this thread: 1 Guest(s)